Gilead Sciences (NASDAQ:GILD) Price Target Cut to $87.00

Share on StockTwits

Gilead Sciences (NASDAQ:GILD) had its price target lowered by investment analysts at Royal Bank of Canada from $89.00 to $87.00 in a report released on Friday, Briefing.com Automated Import reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price would suggest a potential upside of 25.13% from the stock’s current price.

GILD has been the subject of a number of other reports. UBS Group cut shares of Gilead Sciences from a “buy” rating to a “neutral” rating and lifted their price target for the company from $77.00 to $80.00 in a research report on Monday, April 27th. SunTrust Banks upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating and lifted their price target for the company from $70.00 to $73.00 in a research report on Tuesday, May 26th. Cowen reiterated a “buy” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Monday, April 13th. SVB Leerink upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $85.00 to $94.00 in a research report on Wednesday, June 3rd. Finally, Piper Sandler reiterated a “buy” rating and set a $90.00 price target on shares of Gilead Sciences in a research report on Monday, June 8th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $79.63.

NASDAQ:GILD opened at $69.53 on Friday. Gilead Sciences has a twelve month low of $60.89 and a twelve month high of $85.97. The company has a market cap of $87.22 billion, a P/E ratio of -289.70, a P/E/G ratio of 2.34 and a beta of 0.70. The company’s 50-day moving average price is $75.47 and its 200-day moving average price is $73.57. The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 32.17% and a negative net margin of 1.16%. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.24 billion. On average, analysts expect that Gilead Sciences will post 6.79 earnings per share for the current year.

In other news, Director John Francis Cogan sold 2,416 shares of Gilead Sciences stock in a transaction on Monday, May 4th. The shares were sold at an average price of $81.75, for a total value of $197,508.00. Following the transaction, the director now directly owns 57,276 shares of the company’s stock, valued at approximately $4,682,313. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Diane E. Wilfong sold 12,264 shares of Gilead Sciences stock in a transaction on Monday, May 4th. The shares were sold at an average price of $80.09, for a total transaction of $982,223.76. Following the completion of the transaction, the chief accounting officer now directly owns 23,685 shares in the company, valued at $1,896,931.65. The disclosure for this sale can be found here. Insiders have sold a total of 28,079 shares of company stock valued at $2,240,630 in the last 90 days. Insiders own 0.13% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in GILD. Capital International Investors increased its stake in Gilead Sciences by 336.8% in the 1st quarter. Capital International Investors now owns 56,369,657 shares of the biopharmaceutical company’s stock valued at $4,214,200,000 after buying an additional 43,464,551 shares during the period. Capital World Investors boosted its position in shares of Gilead Sciences by 123.0% during the first quarter. Capital World Investors now owns 46,331,318 shares of the biopharmaceutical company’s stock worth $3,463,732,000 after buying an additional 25,555,467 shares during the period. Capital Research Global Investors boosted its position in Gilead Sciences by 12.7% during the first quarter. Capital Research Global Investors now owns 95,982,319 shares of the biopharmaceutical company’s stock valued at $7,175,643,000 after purchasing an additional 10,849,434 shares during the last quarter. APG Asset Management N.V. boosted its position in Gilead Sciences by 237.9% during the first quarter. APG Asset Management N.V. now owns 2,417,175 shares of the biopharmaceutical company’s stock valued at $139,948,000 after purchasing an additional 1,701,818 shares during the last quarter. Finally, First Trust Advisors LP boosted its position in Gilead Sciences by 110.8% during the second quarter. First Trust Advisors LP now owns 3,237,076 shares of the biopharmaceutical company’s stock valued at $249,061,000 after purchasing an additional 1,701,510 shares during the last quarter. 78.74% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What is insider trading?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 

Latest News

Different Types of Research Papers
Different Types of Research Papers
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing


 
© 2006-2020 BBNS.